Original title: foreign media: US government researchers say there is no need for Omicron specific vaccine
Chicago, Feb. 4 (Reuters) - a study conducted in monkeys compared the current modna coronavirus vaccine booster with a vaccine booster specifically targeting the Omicron variant, and the results showed that there was no significant difference in the protective effect between the two, U.S. government researchers said on the 4th, This means that a booster needle specifically for the Omicron variant may not be required.
The study involved monkeys who received two doses of Modena vaccine nine months ago, the report said. In this trial, they were vaccinated with the conventional enhanced needle of Modena new crown vaccine and a specific enhanced needle for the Omicron variant.
The researchers tested all aspects of the monkey's immune response and will expose the monkeys to the virus.
According to relevant research reports, both kinds of reinforcing needles have significantly enhanced the "neutralizing antibody reaction" against all mutants that need attention, including Omicron.
The report pointed out that Modena, baintyco and Pfizer have begun to test a new coronal vaccine booster specifically for the Omicron variant in human clinical trials.
"This means that we don't need to completely redesign the vaccine to specifically target the Omicron variant," said Daniel doeke, a vaccine researcher at the National Institute of allergy and infectious diseases and co-author of the study
Dueck believes that both the original vaccine and the vaccine specifically targeting the Omicron variant can produce a "cross reaction", which means that they can recognize many different variants.